Moderna establishes public health-focused charity; FDA approves AstraZeneca diabetes drug for pediatric use
To help promote public health and healthcare in underserved areas of the world, Moderna will establish a charity with a $50 million endowment.
The Cambridge, MA-based company announced the board of directors’ approval Thursday. The foundation will focus on “charitable, scientific and educational endeavors” with an emphasis on promoting public health and the access to healthcare, the press release said. The foundation will start operations once its status as a 501(c)(3) is approved.
“We view Moderna’s work as only just beginning. On behalf of our growing team, partners and shareholders, we are determined to extend Moderna’s societal impact through the formation of the Moderna Charitable Foundation,” Moderna co-founder Noubar Afeyan said in a press release. “Having experienced the positive impact such charitable foundations can have on those in need, I look forward to the contributions that we will make.”
Bydureon BCise approved for use in adolescents 10 and older by FDA
AstraZeneca’s once-weekly injectable, extended release treatment for type 2 diabetes will now be available for use in children, the company announced Friday.
Bydureon BCise has been approved for the use in children 10 years and older by the FDA to improve glycemic control. The approval is the first for a glucagon-like peptide-1 receptor against GLP-1 RA.
A steady rise in global obesity numbers since the 1990s makes the approval of Bydureon that much more important, AstraZeneca said in the press release.
“This decision is an important milestone for the care of this younger patient population by providing a convenient, once-weekly treatment option,” R&D chief Mene Pangalos said in a press release. “The Phase III data that supported this approval demonstrated the safety and tolerability of exenatide extended-release in younger patients was similar to the proven safety profile of this medicine in adults.”
The drug was first approved in the US in 2017, and by European regulators in August 2018.
The Phase III — dubbed BCB114 — was a 24-week randomized placebo-controlled trial with type 2 diabetes patients treated with either only diet and exercise or with a combination of antidiabetic agents and insulin. A trial for patients younger than 10 has not yet been studied.